April 3rd 2025
Your daily dose of the clinical news you may have missed.
April 1st 2025
Semaglutide 2.4 mg significantly lowered the risk of MACE and mortality in patients with ASCVD and overweight or obesity but without diabetes, researchers reported.
March 31st 2025
March 26th 2025
Data from the phase 2 VENTURE-Oral Dosing Trial of VK2735 is expected in the second half of the year, the company said.
March 21st 2025
The 10 States with the Highest Risk for Cancer
The greatest risk for developing cancer faces residents of South Dakota, where radon levels are the nation's highest, and ranks for alcohol consumption and obesity are poor.
ZUPREME-1 Phase 2b Trial of Petrelentide for Obesity Completes Enrollment
The amylin analog at 5 doses will be compared with placebo when added to a reduced calorie diet and increased physical activity regimen for 42 weeks, said Zealand Pharma.
Cost of Semaglutide, Tirzepatide Prohibitive Despite Significant Benefits
A new economic evaluation estimates that semaglutide would need to drop its current price by 81.9% and tirzepatide by 30.5% to be cost effective.
CagriSema Phase 3 Update: Weight Loss of Nearly 16% Seen in REDEFINE 2 Trial
CagriSema proved superior to placebo in the pivotal phase 3 trial but as in the earlier REDEFINE 1 study fell short of the 25% or greater reduction Novo Nordisk projected.
Investigational Ketogenic Diet Pill BL-001 Shows Significant Weight Loss in Phase 1 Trial
Overweight individuals in the highest dose group with weight loss at day 28 continued to lose weight at the 2-week follow-up, with metabolic changes mimicking ketogenic effects.
Obesity Will Affect One-Half of Adults, One-Third of Youth Worldwide by 2050
Posing an unparalleled threat of premature disease and death globally, the unchecked rise in overweight and obesity requires an urgent 5-year action plan, experts say.
Eli Lilly Expands Zepbound Access with New Vial Doses, Self-Pay Savings
Eli Lilly launched 2 new strengths of Zepbound single-dose vials for self-pay patients, and lowered the price of 2.5 mg and 5 mg vials.
Hims & Hers Super Bowl Ad for Semaglutide "Nothing Short of Reckless," Says Partnership for Safe Medicines
In letters to the FDA and Fox Broadcasting, PSM enumerated the laws abrogated and the potential harms of the ad being viewed by 200 million people on February 9, 2025.
Viking Therapeutics Advances 3 Potential Obesity Treatments Based on Promising 2024 Clinical Trial Results
A GLP-1/GIP dual agonist in both subcutaneous and oral tablet formulations and a novel dual amylin and calcitonin receptor agonist lead the company's pipeline for antiobesity medications.
Enobosarm Preserves Lean Body Mass in Older Adults Treated with Semaglutide for Weight Reduction: Topline Phase 2b Data
In preliminary findings of the phase 2b QUALITY trial, 32% of weight loss in the semaglutide group was from lean mass reduction vs 9.4% in the combined semagutide/enobosarm group.
Novo Nordisk’s Amycretin Achieves Up to 22% Weight Loss in Phase 1b/2a Trial
Weekly subcutaneous injections of amycretin featured a safety profile similar to other incretin-based drugs, according to new topline results.
GLP-1 Mimetic Benefits Are Broad, New Study Finds, But Risks Can't Be Ignored
Incretin-mimetics may have even broader application against disease than scientists can predict, but the risks are real, too, according to a study of 2 million.
Ascletis Enters Small Molecule Oral GLP-1 RA Category with Positive Phase 1a Findings in Obesity
The properties of ASC30 may allow the small molecule GLP-1 RA to be formulated as a monthly injection and daily oral tablet, Ascletis said.
Semaglutide 7.2 mg Achieves Weight Reduction of 21% in Late-Stage STEP UP Trial
The 20.7% weight loss with the high-dose of semaglutide bested the mean reduction of 17.5% seen with semaglutide 2.4 mg, according to Novo Nordisk.
Obesity and Hypertension: Addressing Misconceptions in Clinical Practice
Caissa Troutman, MD, stresses the importance of building trust with patients through active listening and consistent, non-judgmental communication.
GLP-1/GIP Dual Agonist HRS9531 Shows Promising Phase 2 Data for Obesity Management
More than half of study participants receiving the dual incretin agonist had weight loss of 20% or greater, with no evidence of a plateau and only mild AEs.
Early Hypertensive Screening in Patients with Obesity: Expert Perspective
Obesity medicine expert Caissa Troutman, MD, suggests using annual physicals as a "gateway" to identify patients with obesity with elevated blood pressure.
FDA Proposes Sustained 5% Weight Loss to Establish Efficacy of New Antiobesity Medications
In an unusual step, the agency's draft guidance recommends the efficacy benchmark for drug approval while emphasizing clinical trial structure and cohort development.
FDA Approves Tirzepatide as First Drug for Obstructive Sleep Apnea with Obesity
This marks the second indication for tirzepatide in just more than a year, following its November 2023 approval for adults with obesity or overweight and weight-related medical problems.
CagriSema Leads to Weight Reduction of Approximately 23% in Phase 3 REDEFINE 1 Clinical Trial, Short of the 25% Expected
The 22.7% weight loss at 68 weeks places CagriSema essentially on par with, not superior to, competing antiobesity drugs including Lilly's tirzepatide.
Future of Obesity Care: 3 Wishes from Thought Leader Donna Ryan, MD
When asked about her 3 wishes for the future of obesity care, Donna Ryan, MD, told Patient Care that she had just one: access.
Investigational Maridebart Cafraglutide Shows Promise for Obesity, T2D: Daily Dose
Tirzepatide Superior to Semaglutide in Weight Loss Trial: Daily Dose
Expert Perspectives 2024: The Dynamic Future of Obesity Medicine, with Donna Ryan, MD
The future of obesity medicine is filled with promise as GLP-1 RAs and other peptides continue to demonstrate pluripotency in metabolic disease.
Emerging Obesity Research to Watch For in 2025
Donna Ryan, MD, highlights exciting advancements in weight loss and metabolic treatments, particularly involving GLP-1 RAs and related therapies.
Antiobesity Drugs May Help Curb Alcohol Consumption: Daily Dose
The Evolving Perception and Utilization of Antiobesity Drugs: Expert Discussion
Donna Ryan, MD, highlights how the media has helped to reframe obesity as a chronic disease and how antiobesity drugs are transforming metabolic disease treatment.
Pivotal Obesity Trials in 2024: A Conversation with Donna Ryan, MD
Donna Ryan, MD, discusses the most significant clinical trials published this year in the field of obesity medicine.
More than Half of US Adults Eligible for Semaglutide: Daily Dose
Tirzepatide Bests Semaglutide for Weight Loss by 47% in Head-to-Head Trial
"Twincretin" tirzepatide-treated participants in SURMOUNT-5 lost a mean 50 lbs vs an average loss of 33 lbs for those treated with semaglutide.